or Try an Advanced Search...

    Disorders Stocks List

    Symbol Grade Name % Change
    BAX F Baxter International Inc. 0.40
    CPRX C Catalyst Pharmaceutical Partners, Inc. 0.82
    CGTX C Cognition Therapeutics, Inc. -1.01
    CORT C Corcept Therapeutics Incorporated 0.83
    DXR C Daxor Corporation 1.06
    ELDN B Eledon Pharmaceuticals, Inc. 7.14
    ELYM C Eliem Therapeutics, Inc -1.71
    XGN D Exagen Inc. 9.89
    FULC D Fulcrum Therapeutics, Inc. 4.80
    IGC C India Globalization Capital Inc. 2.93
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Medical Care Facilities Medical Instruments & Supplies
    Related Stock Lists: Medicine Biopharmaceutical Epilepsy Pharmaceutical Alzheimer's Disease Biotechnology Health Sciences Kidney Failure Medication Pain Parkinson's Disease Psychiatric Diagnosis Aging Associated Diseases Alpha 1 Antitrypsin Anemia Angioedema Anthrax Antiprogestogens Antitrypsin Deficiency Audiology

    Related ETFs - A few ETFs which own one or more of the above listed Disorders stocks.

    Symbol Grade Name Weight
    PBE B PowerShares Dynamic Biotech & Genome 7.93
    IBRN D iShares Neuroscience and Healthcare ETF 7.44
    FBT C First Trust Amex Biotech Index Fund 6.56
    XPH D SPDR S&P Pharmaceuticals ETF 5.01
    PSIL F AdvisorShares Psychedelics ETF 4.7
    View all Disorders ETFs...
    Compare ETFs
    Compare FBT to XPH Compare IBRN to XPH Compare XPH to PSIL

        Disorders Stocks Recent News

        Date Stock Title
        May 15 CPRX 2 Incredible Growth Stocks to Buy Hand Over Fist Right Now
        May 14 BAX Baxter's (BAX) Clinolipid Gets FDA's Expanded Indication
        May 14 FULC Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?
        May 14 FULC Fulcrum Therapeutics Inc (FULC) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
        May 13 FULC Fulcrum upgraded by Goldman Sachs ahead of Phase 3 data
        May 13 FULC Deep Dive Into Fulcrum Therapeutics Stock: Analyst Perspectives (4 Ratings)
        May 13 BAX Baxter's Clinolipid gets FDA approval for use in infants
        May 13 XGN Exagen, Inc. (XGN) Q1 2024 Earnings Call Transcript
        May 13 FULC Sanofi strikes $1bn deal with Fulcrum for muscular dystrophy drug
        May 13 FULC Fulcrum Therapeutics, Inc. (FULC) Q1 2024 Earnings Call Transcript
        May 13 FULC Sanofi gains license for ex-U.S. rights to Fulcrum muscular dystrophy candidate
        May 13 BAX (BAX) - Analyzing Baxter Intl's Short Interest
        May 13 XGN Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates
        May 13 BAX Baxter Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication
        May 13 FULC Fulcrum Therapeutics Q1 2024 Earnings: Misses Analyst Net Income Projections Amid Strategic ...
        May 13 XGN Exagen beats top-line and bottom-line estimates; raises FY24 outlook
        May 13 XGN Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year
        May 13 FULC Sanofi gambles $80M on Fulcrum’s muscular dystrophy drug
        May 13 FULC Fulcrum Therapeutics GAAP EPS of -$0.43 in-line
        May 13 CORT 3 High Insider Ownership US Growth Companies With Earnings Growth Up To 70%
        Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Medical Care Facilities Medical Instruments & Supplies
        Related Stock Lists: Biopharmaceutical Medicine Organ Systems Anemia Angioedema Bone Disease Dystrophy Epilepsy Genodermatoses Hematology Hematopathology Hereditary Angioedema Hypertension Kidney Failure Neurological Disorders Rare Diseases Syndromes Acromegaly Aging Associated Diseases
        Disorders

        Disorder may refer to randomness, non-order, or no intelligible pattern. Disorder may also refer to:

        More about Disorders
        Browse All Tags